Update: Skystar Bio Pharmaceuticals Earnings - Boost In Q2 Revenue

Aug.15.14 | About: Skystar Bio (SKBI)

Summary

Skystar increased revenue even in the face of transitioning to large scale manufacturing.

This reinforces my positive outlook for the company.

I did note in my last article that the new manufacturing facility will be a catalyst for the company.

Skystar Bio Pharmaceuticals (NASDAQ:SKBI) is in the process of transitioning from small-scale lab production to large-scale factory manufacturing. Although this is causing some growing pains, the company still increased revenue by 25.6% in Q2 to $14.2 million. The new facility is being built to produce vaccines which have a higher gross margin than veterinary medicine. Part of the growing pains for Q2 include a decrease in vaccine revenue of 99% year-over-year as the transition takes place. Veterinary medicine revenue increased 36.7% to $8.6 million.

The transition did cause a hiccup as net income decreased 26.3% year-over-year. However, this was the result of the gross margin decrease from 52.6% last year to 44.7% in Q2. Since more of the lower margin veterinary medicines were sold than vaccines in Q2 due to the transition, the overall gross margin decreased, thus reducing profitability. However, this is just a temporary condition as the new vaccine facility is still being constructed.

The company's overall revenue growth in the face of the transition reinforces my positive outlook on Skystar. As noted in my original article on Skystar, I pointed out that the new vaccine facility will provide a catalyst for the company as vaccines produce a higher gross margin of about 70% as compared to Skystar's pre-transition gross margin of 51%. Therefore, once the new facility is in place and contributing to sales, I expect Skystar's gross margin to increase, leading to earnings growth in the future.

Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.